Volume 70, Issue 4, Pages (October 2016)

Slides:

Advertisements

Similar presentations

Volume 72, Issue 1, Pages (July 2017)

Advertisements

Volume 70, Issue 3, Pages (September 2016)

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 70, Issue 5, Pages (November 2016)

Volume 51, Issue 2, Pages (February 2007)

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Volume 373, Issue 9660, Pages (January 2009)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Global Trends in Testicular Cancer Incidence and Mortality

Volume 58, Issue 5, Pages (November 2010)

Volume 53, Issue 4, Pages (April 2008)

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 70, Issue 1, Pages (July 2016)

Volume 61, Issue 5, Pages (May 2012)

Volume 60, Issue 5, Pages (November 2011)

Volume 73, Issue 6, Pages (June 2018)

Volume 51, Issue 4, Pages (April 2007)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 72, Issue 5, Pages (November 2017)

Volume 62, Issue 6, Pages (December 2012)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 5, Pages (November 2015)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 6, Pages (June 2015)

Volume 73, Issue 4, Pages (April 2018)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 66, Issue 5, Pages (November 2014)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 65, Issue 6, Pages (June 2014)

Volume 60, Issue 6, Pages (December 2011)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Volume 58, Issue 3, Pages (September 2010)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 71, Issue 6, Pages (June 2017)

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Volume 373, Issue 9660, Pages (January 2009)

Volume 72, Issue 1, Pages (July 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.

Volume 51, Issue 2, Pages (February 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Presentation transcript:

Volume 70, Issue 4, Pages 684-691 (October 2016) Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7 Sophie D. Fosså, Fredrik Wiklund, Olbjørn Klepp, Anders Angelsen, Arne Solberg, Jan-Erik Damber, Morten Hoyer, Anders Widmark European Urology Volume 70, Issue 4, Pages 684-691 (October 2016) DOI: 10.1016/j.eururo.2016.03.021 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Cumulative incidence of (A) death from prostate cancer and (B) death from any cause. European Urology 2016 70, 684-691DOI: (10.1016/j.eururo.2016.03.021) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Forest plot of hazard ratios of (A) prostate-cancer-specific mortality and (B) overall mortality in the endocrine plus radiotherapy group compared with the endocrine only group stratified by age at start of treatment, vesicle infiltration, World Health Organization (WHO) grade, T stage, risk group, and prostate-specific antigen (PSA) level. CI = confidence interval; HR = hazard ratio. European Urology 2016 70, 684-691DOI: (10.1016/j.eururo.2016.03.021) Copyright © 2016 European Association of Urology Terms and Conditions